Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

NCT01111825 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Temsirolimus
DRUG: Neratinib

Sponsor

Puma Biotechnology, Inc.